Patent SG-11201901505S-A (SG)
Title: I domain chimeric antigen receptor specific to icam-1
Inventor: JIN MOONSOO
IPC: C12N15/00
Filed: 2017-08-11
Abstract: Nilycj domain hinge 5' Li' (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WIPO I PCT 0111111010 0111 °nolo III m lionimommo oimIE (10) International Publication Number WO 2018/052594 Al (51) International Patent Classification: A01N 63/00 (2006.01) CO7K 1/00 (2006.01) A61K 48/00 (2006.01) C12N 15/00 (2006.01) C12N 5/071 (2010.01) C07H 21/04 (2006.01) (21) International Application Number: PCT/US2017/046630 (22) International Filing Date: 11 August 2017 (11.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/383,139 02 September 2016 (02.09.2016) US 62/419,817 09 November 2016 (09.11.2016) US (71) Applicant: CORNELL UNIVERSITY [US/US]; Center for Technology Licensing (\"CTL\"), 395 Pine Tree Road, Suite 310, Ithaca, New York 14850 (US). (72) Inventor: JIN, Moonsoo; Center for Technology Licensing (\"CTL\"), 395 Pine Tree Road, Suite 310, Ithaca, New York 14850 (US). (74) Agent: KUNG, Viola T. et al.; Perkins Coie LLP - PAO, P.O. Box 1247, Seattle, Washington 98111-1247 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: I DOMAIN CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO ICAM-1 CDCE128 4-1SS TMI Cyt Cyt LTR :SP SA CAR FIG. 1D (57) : The present invention relates to chimeric antigen receptors (CARs) specific to Intercellular adhesion molecule-1 (ICAM-1) comprising I domain of the aL subunit of human lymphocyte function-associated antigen 1 (LFA-1 ). The invention particu- larly relates to CARs comprising human I domains having different affinities (1 mM to 1 nM Kd) to ICAM-1. CAR-T cells comprising O human I domain having a low affinity (1 to 200 uM Kd) to ICAM-1 can avoid targeting healthy tissues with basal ICAM-1 expression cc while simultaneously exhibiting increased potency and long-term efficacy against tumor tissues with high ICAM-1 expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising O human I domain to a subject suffering from cancer, whereby the CAR-T cells bind to the cancer cells overexpressing ICAM-1 and kill the cancer cells. C